Trade Name

Abilify Asimtufii

Request Type

New Registration

Drug Type

NCE

Approval Date

Sat, 02/01/2025 - 12:00

SFDA Approved Use

- Indicated for the treatment of schizophrenia.
- Maintenance monotherapy treatment of bipolar I disorder in adults.